{
    "clinical_study": {
        "@rank": "58526", 
        "arm_group": {
            "arm_group_label": "Cohort"
        }, 
        "brief_summary": {
            "textblock": "This multicenter, observational study will assess the efficacy and the safety of Pegasys\n      (peginterferon alfa 2a) in dual- or triple therapy in patients with chronic hepatitis C.\n      Patients will receive Pegasys and/or ribavirin and/or a protease inhibitor according to\n      local guidelines. Data will be collected for 96 weeks."
        }, 
        "brief_title": "An Observational Study of Pegasys in Dual- or Triple-Therapy in Patients With Chronic Hepatitis C", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatitis C, Chronic", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis, Chronic", 
                "Hepatitis C", 
                "Hepatitis C, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients, >/= 18 years of age\n\n          -  Diagnosis of chronic hepatitis C\n\n          -  Patients receiving treatment with Pegasys and/or Copegus (ribavirin) and/or a\n             protease inhibitor according to local label\n\n        Exclusion Criteria:\n\n          -  Contraindications against Pegasys or Copegus\n\n          -  Not willing or unable to sign written informed consent form"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Patients with chronic hepatitis C infection"
            }
        }, 
        "enrollment": {
            "#text": "7500", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 3, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01679834", 
            "org_study_id": "ML25724"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 5, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Herne", 
                    "country": "Germany", 
                    "zip": "44623"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_groups": "1", 
        "official_title": "A Roche Project in Cooperation With the Bng (Association of German Resident Gastroenterologists) for Quality Assurance in the Dual- or Triple-therapy of Chronic Hepatitis C With Peg-(40kd)-Interferon Alfa 2a (Pegasys) at Hepatology Centers", 
        "overall_contact": {
            "email": "global.rochegenentechtrials@roche.com", 
            "last_name": "Reference Study ID Number: ML25724 www.roche.com/about_roche/roche_worldwide.htm", 
            "phone": "888-662-6728 (U.S. Only)"
        }, 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: BfArM (Federal Institute for Drugs and Medical Devices)"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Sustained virological response", 
            "safety_issue": "No", 
            "time_frame": "24 weeks after end of treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01679834"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Rapid virological response", 
                "safety_issue": "No", 
                "time_frame": "4 weeks after start of treatment"
            }, 
            {
                "measure": "Early Virological Response", 
                "safety_issue": "No", 
                "time_frame": "12 weeks after start of treatment"
            }, 
            {
                "measure": "Safety: incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "up to 24 weeks after end of treatment"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2011", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}